The Stockbrokers Society issues research report on Techniclone International.LOS ANGELES--(BUSINESS WIRE)--Sept. 10, 1996--Techniclone International Corp. (NASDAQ/Small Cap:TCLN), a Tustin, Calif., biotech company that appears to have the lead in developing a "magic bullet (jargon) magic bullet - (Or "silver bullet" from vampire legends) A term widely used in software engineering for a supposed quick, simple cure for some problem. E.g. "There's no silver bullet for this problem". " treatment for a cancer, is the subject of a research report issued by the Stockbrokers Society. The four-page report, which was commissioned by Techniclone, is available at no charge from the Stockbrokers Society by calling 800/552-2855 or faxing 818/957-1424. "Magic bullet" refers to a treatment that delivers a cancer-killing agent directly to the cancerous cells in sufficient quantity to destroy them, yet does not harm healthy tissue. Conventional therapy -- surgery, chemotherapy and radiation -- typically fails to differentiate between diseased and healthy tissue. Technicolone has three patented magic-bullet technologies that, in pre-clinical studies, have increased the concentration of cancer-killing agents delivered to tumors by five to eight times. All three, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the company, hold promise for a family of new diagnostic and therapeutic products that are effective against solid cancers, such as those that afflict af·flict tr.v. af·flict·ed, af·flict·ing, af·flicts To inflict grievous physical or mental suffering on. [Middle English afflighten, from afflight, the prostate, lung, colon, breast and pancreas. Tumor necrosis tumor necrosis Death of tumor tissue, a common event in aggressive CAs in which the tumor rapidly outgrows its blood supply, resulting in tumor cell death. Cf Apoptosis. therapy (TNT TNT: see trinitrotoluene. TNT in full trinitrotoluene Pale yellow, solid organic compound made by adding nitrate (−NO2) groups to toluene. ) targets dead or dying tissue at the interior of solid tumors. Vasopermation enhancement (VE) causes tumor vessel walls to become more permeable, thereby promoting a three- to four-fold increase in drug uptake by tumerous tissue cells. And modified antibody technology (MAT) involves chemical modification In biochemistry, chemical modification is the technique of chemically reacting a protein or nucleic acid with chemical reagents. Chemical modification can have several goals, such as
To further development of the TNT technology, Techniclone has formed two strategic alliances. Techniclone and Cambridge Antibody Technology Ltd., of Great Britain Great Britain, officially United Kingdom of Great Britain and Northern Ireland, constitutional monarchy (2005 est. pop. 60,441,000), 94,226 sq mi (244,044 sq km), on the British Isles, off W Europe. The country is often referred to simply as Britain. will share equally in capital costs and clinical-trial expenses. These trials will be conducted in England, where they are likely to proceed at a faster pace than similar studies in the United States. The second alliance is with Brilliance Shanghai Pharmaceutics of China. Brilliance is funding development of TNT-based products for cancer therapy and diagnosis, and is conducting human clinical trials. In return for a 10% sales royalty, Brilliance has marketing rights throughout China. Meanwhile, clinical trials for Techniclone's most developed product, Oncolym, are in their final phase, having shown encouraging results in earlier tests. Oncolym, which is a trademark owned by Alpha Therapeutic Corp. (the U.S. subsidiary of The Green Cross Corp. of Japan), is a radiopharmaceutical radiopharmaceutical /ra·dio·phar·ma·ceu·ti·cal/ (-fahr?mah-soo´ti-k'l) a radioactive pharmaceutical, nuclide, or other chemical used for diagnostic or therapeutic purposes. drug for the treatment of lymph cancer. Also known as non-Hodgkin's B-cell lymphoma, this is the disease that killed Jacqueline Onassis. CONTACT: Stockbrokers Society Robert A. Dresser, 800/552-2855 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion